These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 31383678

  • 1. High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.
    Lind-Holst M, Hartling UB, Christensen AE.
    BMJ Case Rep; 2019 Aug 04; 12(8):. PubMed ID: 31383678
    [Abstract] [Full Text] [Related]

  • 2. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report.
    Shafferman A, Birmingham JD, Cron RQ.
    Pediatr Rheumatol Online J; 2014 Aug 04; 12():26. PubMed ID: 25045337
    [Abstract] [Full Text] [Related]

  • 3. Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm.
    Guillaume MP, Reumaux H, Dubos F.
    Cardiol Young; 2018 May 04; 28(5):739-742. PubMed ID: 29455693
    [Abstract] [Full Text] [Related]

  • 4. Kawasaki disease shock syndrome complicated with macrophage activation syndrome in a 5-month old boy: A case report.
    Lin Y, Shi L, Deng YJ, Liu Y, Zhang HW.
    Medicine (Baltimore); 2019 Jan 04; 98(4):e14203. PubMed ID: 30681594
    [Abstract] [Full Text] [Related]

  • 5. Anakinra and hepatotoxicity in pediatric rheumatology: a case series.
    Martins FR, Azevedo AC, Ganhão S, Aguiar F, Rodrigues M, Brito I.
    Pediatr Rheumatol Online J; 2023 Oct 06; 21(1):112. PubMed ID: 37803456
    [Abstract] [Full Text] [Related]

  • 6. Macrophage activation syndrome in Kawasaki disease.
    Mukherjee D, Pal P, Kundu R, Niyogi P.
    Indian Pediatr; 2014 Feb 06; 51(2):148-9. PubMed ID: 24632699
    [Abstract] [Full Text] [Related]

  • 7. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
    Pilania RK, Jindal AK, Johnson N, Prithvi A, Vignesh P, Suri D, Rawat A, Gupta A, Singh S.
    Rheumatology (Oxford); 2021 Jul 01; 60(7):3413-3419. PubMed ID: 33221920
    [Abstract] [Full Text] [Related]

  • 8. Macrophage activation syndrome in children with Kawasaki disease: diagnostic and therapeutic approaches.
    Han SB, Lee SY.
    World J Pediatr; 2020 Dec 01; 16(6):566-574. PubMed ID: 32418074
    [Abstract] [Full Text] [Related]

  • 9. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids.
    Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F.
    J Clin Rheumatol; 2011 Jan 01; 17(1):23-7. PubMed ID: 21169853
    [Abstract] [Full Text] [Related]

  • 10. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra.
    Loh NK, Lucas M, Fernandez S, Prentice D.
    Intern Med J; 2012 Dec 01; 42(12):1358-62. PubMed ID: 23253002
    [Abstract] [Full Text] [Related]

  • 11. Use of Infliximab in the Treatment of Macrophage Activation Syndrome Complicating Kawasaki Disease.
    Rivera-Rodriguez L, Pardo-Díaz E, Moreno-Espinosa S, Scheffler-Mendoza S, Ruiz-Ontiveros MA, Garrido-García LM, Iglesias-Amaya A, Yamazaki-Nakashimada MA.
    J Pediatr Hematol Oncol; 2021 Apr 01; 43(3):e448-e451. PubMed ID: 32079989
    [Abstract] [Full Text] [Related]

  • 12. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
    Tremoulet AH, Jain S, Kim S, Newburger J, Arditi M, Franco A, Best B, Burns JC.
    Contemp Clin Trials; 2016 May 01; 48():70-5. PubMed ID: 27080929
    [Abstract] [Full Text] [Related]

  • 13. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children.
    Lee PY, Day-Lewis M, Henderson LA, Friedman KG, Lo J, Roberts JE, Lo MS, Platt CD, Chou J, Hoyt KJ, Baker AL, Banzon TM, Chang MH, Cohen E, de Ferranti SD, Dionne A, Habiballah S, Halyabar O, Hausmann JS, Hazen MM, Janssen E, Meidan E, Nelson RW, Nguyen AA, Sundel RP, Dedeoglu F, Nigrovic PA, Newburger JW, Son MBF.
    J Clin Invest; 2020 Nov 02; 130(11):5942-5950. PubMed ID: 32701511
    [Abstract] [Full Text] [Related]

  • 14. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
    Koné-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, Meinzer U, Cherqaoui B, Galeotti C, Boukhedouni N, Agostini H, Arditi M, Lambert V, Piedvache C.
    Arthritis Rheumatol; 2021 Jan 02; 73(1):151-161. PubMed ID: 32779863
    [Abstract] [Full Text] [Related]

  • 15. Intravenous administration of anakinra in children with macrophage activation syndrome.
    Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S.
    Pediatr Rheumatol Online J; 2021 Jun 29; 19(1):98. PubMed ID: 34187503
    [Abstract] [Full Text] [Related]

  • 16. Severe Late-Onset Kawasaki Disease Successfully Treated With Anakinra.
    Blonz G, Lacroix S, Benbrik N, Warin-Fresse K, Masseau A, Trewick D, Hamidou M, Stephan JL, Néel A.
    J Clin Rheumatol; 2020 Mar 29; 26(2):e42-e43. PubMed ID: 32073531
    [No Abstract] [Full Text] [Related]

  • 17. Acute respiratory distress syndrome associated with macrophage activation syndrome in systemic lupus erythematosus: A case report and literature review.
    Chang ES, Yu HH, Wu CE, Chan TM.
    Medicine (Baltimore); 2022 Feb 04; 101(5):e28612. PubMed ID: 35119005
    [Abstract] [Full Text] [Related]

  • 18. Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review.
    García-Pavón S, Yamazaki-Nakashimada MA, Báez M, Borjas-Aguilar KL, Murata C.
    J Pediatr Hematol Oncol; 2017 Aug 04; 39(6):445-451. PubMed ID: 28562511
    [Abstract] [Full Text] [Related]

  • 19. [Macrophage activation syndrome and Kawasaki disease: Four new cases].
    Dumont B, Jeannoel P, Trapes L, Rolland E, Gay C, Stephan JL.
    Arch Pediatr; 2017 Jul 04; 24(7):640-646. PubMed ID: 28583781
    [Abstract] [Full Text] [Related]

  • 20. Anakinra And Etanercept Combination Treatment in a Child With Severe, Nonresponsive Kawasaki Disease.
    Walser M, Hermann M, Hufnagel M, Haas NA, Fischer M, Dalla-Pozza R, Jakob A.
    Pediatr Infect Dis J; 2020 Oct 04; 39(10):e310-e313. PubMed ID: 32618930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.